Large-scale selective antibiotic prophylaxis during the 2004 cholera outbreak in Douala (Cameroon);Antibioprophylaxie ciblée à large échelle au cours de l'épidémie de choléra de Douala en 2004

Cahiers Sante

Volumn 17, Issue 2, 2007, Pages 63-68

  Guévart, Édouard ^a,b,c   Noeske, Jürgen ^d   Sollé, Jérémie ^a   Mouangue, Antoine ^a   Bikoti, Joseph Marie ^a  

^a Delegation Provinciale de la Sante Publique du Littoral   (Cameroon)

^b Service de Cooperation et d'Action Culturelle de I'Ambassade de France a Yaounde   (Cameroon)

^c Ambassade de France en Egypte   (France)

^d Financial Systems Development Section   (Germany)

Author keywords

Antibiotherapy; Cameroon; Cholera; Epidemiology; Therapeutic efficiency

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; DOXYCYCLINE;

ARTICLE; CAMEROON; CHEMOPROPHYLAXIS; CHOLERA; EPIDEMIC; HUMAN; RETROSPECTIVE STUDY;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CAMEROON; CHEMOPREVENTION; CHOLERA; DISEASE OUTBREAKS; DOXYCYCLINE; HUMANS; RETROSPECTIVE STUDIES;

EID: 35948987684     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: 10.1684/san.2007.0072     Document Type: Article

References (49)

1. Garrigue P, Ndayo M, Sicard JM, et al. Résistance aux antibiotiques des souches de Vibrio cholerae El Tor isolées à Douala (Cameroun). Bull Soc path Exot 1986; 79: 305-12.
2. Shears P. Recent developments in cholera. Curr Opin Infect Dis 2001; 14: 553-8.
3. Organisation mondiale de la santé (OMS). Guide pour la lutte contre le choléra. Genève: OMS, 1993.
4. Guévart É, Noeske J, Solle J, et al. Déterminants du choléra à Douala. Med Trop 2006; 66: 283-91.
5. Commeyras C, Ndo JR, Merabet O, Kone H, Rakotondrabe FP. Comportement de recours aux soins et aux médicaments au Cameroun. Sante 2006; 16: 5-12.
6. Commeyras C, Ndo JR, Merabet O, Kone H, Rakotondrabe FP. Caractéristiques de la consommation de soins et de médicaments au Cameroun. Sante 2006; 16: 13-97.
7. Guévart É, Solle J, Mouangue A, et al. Évolution de la sensibilité de Vibrio cholerae 01 après utilisation prolongée d'antibiotiques en traitement et en prophylaxie au cours de l'épidémie de choléra de Douala (Cameroun) 2004. Med Mal Infect 2006; 36: 329-34.
8. Durrheim D. Prevention of cholera. Lancet 2004; 363: 897-8.
9. Noeske J, Guévart É, Kuaban C, et al. Routine use of antimicrobial drugs during the 2004 cholera epidemic in Douala, Cameroon. East Afr Med J 2006; 83: 363-8.
10. Calain P, Chaine J-P, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22: 2444-51.
11. Richie E, Punjabi NH, Sidharta Y, Peetosutan K, Sukandar M, Wasserman SS. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in north Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18: 2399-410.
12. Hutton G, Haller L. Evaluation of the costs and benefits of water and sanitation improvements at the global level. In: Water, sanitation and health protection of the human environment. Geneva: World Health Organization, 2004.
13. Van Damme W, Van Lerberghe W. Strengthening health services to control epidemics: empirical evidence from Guinea on its cost-effectiveness. Trop Med Int Health 2004; 9: 281-91.
14. Farmer JJ, Kelly MT. Enterobacteriaceae. In: Balows A, Hausler Jr. WJ, Herman KL, Isenberg HD, Shadomy HJ, eds. Manual of Clinical Microbiology. Fifth edition. Washington (DC): American Society for Microbiology, 1991.
15. Dalsgaard A, Forslund A, Bodhidatta L, et al. A high proportion of Vibrio cholerae strains isolated from children with diarrhoea in Bangkok, Thailand are multiple antibiotic resistant and belong to heterogenous non-O1, non-O139 O-serotypes. Epidemiol Infect 1999; 122: 217-26.
16. Dromigny JA, Rakoto-Alson O, Rajaonatahina D, Migliani R, Ranjalahy J, Mauclere P. Emergence and rapid spread of tetracycline-resistant Vibrio cholerae strains, Madagascar. Emerg Infect Dis 2002; 8: 336-8.
17. Memon IA, Murtaza G. Drug sensitivity pattern of cholera in children. J Pak Med Assoc 2002; 52: 347-8.
18. Phantouamath B, Sithivong N, Sisavath L, et al. Transition of drug susceptibilities of Vibrio cholerae O1 in Lao People's Democratic Republic. Southeast Asian J Trop Med Public Health 2001; 32: 95-9.
19. Dalsgaard A, Forslund A, Serichantalergs O, Sandvang D. Distribution and Content of Class 1 Integrons in Different Vibrio cholerae O-Serotype Strains Isolated in Thailand. Antimicrob Agents Chemother 2000; 44: 1315-21.
20. Dalsgaard A, Forslund A, Sandvang D, Arntzen L, Keddy K. Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons. J Antimicrob Chemother 2001; 48: 827-38.
21. Isaac-Marquez AP, Lezama-Davila CM, Eslava-Campos C, Navarro-Ocana A, Craviotouuintana A. Serotypes of Vibrio cholerae non-O1 isolated from water supplies for human consumption in Campeche, Mexico and their antibiotic susceptibility pattern. Mem Inst Oswaldo Cruz 1998; 93: 17-22.
22. Iwanaga M, Toma C, Miyazato T, Insisiengmay S, Nakasone N, Ehara M. Antibiotic Resistance Conferred by a Class I Integron and SXT Constin in Vibrio cholerae O1 Strains Isolated in Laos. Antimicrob Agents Chemother 2004; 48: 2364-9.
23. Petroni A, Corso A, Melano R, et al. Plasmidic Extended-Spectrum Bêta-Lactamases in Vibrio cholerae O1 El Tor Isolates in Argentina. Antimicrob Agents Chemother 2002; 46: 1462-8.
24. Waldor MK, Tschäpe H, Mekalanos JJ. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139. J Bacteriol 1996; 178: 4157-65.
25. Martin C, et un groupe d'experts. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie. Actualisation 1999. Conférences de consensus. Paris: Société française d'anesthésie et de réanimation (SFAR); Agence nationale d'accréditation et d'évaluation en santé (Anaes), 1999.
26. Berche P. La réémergence du choléra. Médecine thérapeutique 1998; 4: 213-22.
27. Borroto RJ, Martinez-Piedra R. Geographical patterns of cholera in Mexico, 1991-1996. Int J Epidemiol 2000; 29: 764-72.
28. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, Genetics, and Ecology of Toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 1998; 62: 1301-14.
29. Soomro AL, Junejo N. Vibrio cholerae in the environment. J Coll Physicians Surg Pak 2004; 14: 509-12.
30. Gil Al, Louis VR, Rivera IN, et al. Occurrence and distribution of Vibrio cholerae in the coastal environment of Peru. Environ Microbiol 2004; 6: 699-706.
31. Huq A, Small EB, West PA, Huq MI, Rahman R, Colwell RR. Ecological relationships between Vibrio cholerae and planktonic crustacean copepods. Appl Environ Microbiol 1983; 45: 275-83.
32. Madico G, Checkley W, Oilman RH, et al. Active surveillance for Vibrio cholerae O1 and vibriophages in sewage water as a potential tool to predict cholera outbreaks. J Clin Microbiol 1996; 34: 2968-72.
33. Ashbolt NJ. Microbial contamination of drinking water and disease outcomes in developing regions. Toxicology 2004; 198: 229-38.
34. Colwell RR, Huq A, Sirajul Islam M, et al. Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci USA 2003; 100: 1051-5.
35. Sinkala M, Makasa M, Mwanza F, et al. Centers for Disease Control and Prevention (CDC). Cholera epidemic associated with raw vegetables-Lusaka, Zambia, 2003-2004. MMWR Morb Mortal Wkly Rep 2004; 53: 783-6.
36. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363: 223-33.
37. Sen Gupta RG, Sircar BK, Mondai S, et al. Effects of doxycycline on transmission of Vibrio cholerae infection among family contacts of cholera patients in Calcutta. Bull World Health Organ 1978; 56: 323-6.
38. Goh Kt. Teo Sh, Lam S, Ling Mk. Person-to-person transmission of cholera in a psychiatric hospital. J Infect 1990; 20: 193-200.
39. Guévart É, Solle J, Noeske J, Amougou G, Mouangue A, Bita Fouda A. Antibioprophylaxie de masse contre le choléra dans la prison centrale de Douala (New Bell) au cours de l'épidémie de 2004. Sante 2005; 15: 225-7.
40. Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990; 300: 1619-21.
41. Dutta D, Bhattacharya SK, Bhattacharya MK, et al. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae 0139 infection. J Antimicrob Chemother 1996; 37: 575-81.
42. Khan W, Bennish M, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996; 348: 296-300.
43. Usubutun S, Agalar C, Diri C, Turkyilmaz R. Single dose ciprofloxacin in cholera. Eur J Emerg Med 1997; 4: 145-9.
44. Torres Codeço C. Endemic and epidemic dynamics of cholera : the role of the aquatic reservoir. BMC Infect Dis 2001; 1: 1.
45. Acosta CJ, Galindo CM, Kimario J, et al. Cholera Outbreak in Southern Tanzania : Risk Factors and Patterns of Transmission. Emerg Infect Dis 2001; 7: 583-7.
46. Cohen MB, Giannella RA, Bean J, et al. Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine. Infect Immun 2002; 70: 1965-70.
47. Garcia L, Diaz Jidy M, Garcia H, et al. The Vaccine Candidate Vibrio cholerae 638 Is Protective against Cholera in Healthy Volunteers. Infect Immun 2005; 73: 3018-24.
48. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with vibrio cholerae O1 EI Tor Inaba three months after vaccination. Infect Immun 1999; 67: 6341-5.
49. Taylor DN, Sanchez JL, Castro JM, et al. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR Plus CVD 111, in United States military personnel stationed in panama. Infect Immun 1999; 67: 2030-4.